vs

Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Eventbrite, Inc. (EB). Click either name above to swap in a different company.

BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $73.5M, roughly 1.1× Eventbrite, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -11.1%, a 17.9% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -3.9%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-60.9M).

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

BLLN vs EB — Head-to-Head

Bigger by revenue
BLLN
BLLN
1.1× larger
BLLN
$83.5M
$73.5M
EB
Growing faster (revenue YoY)
BLLN
BLLN
+121.3% gap
BLLN
117.4%
-3.9%
EB
Higher net margin
BLLN
BLLN
17.9% more per $
BLLN
6.8%
-11.1%
EB
More free cash flow
BLLN
BLLN
$67.3M more FCF
BLLN
$6.5M
$-60.9M
EB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BLLN
BLLN
EB
EB
Revenue
$83.5M
$73.5M
Net Profit
$5.7M
$-8.2M
Gross Margin
69.9%
68.1%
Operating Margin
11.5%
-12.4%
Net Margin
6.8%
-11.1%
Revenue YoY
117.4%
-3.9%
Net Profit YoY
138.3%
2.5%
EPS (diluted)
$0.10
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLLN
BLLN
EB
EB
Q4 25
$73.5M
Q3 25
$83.5M
$71.7M
Q2 25
$72.8M
Q1 25
$73.8M
Q4 24
$76.5M
Q3 24
$38.4M
$77.8M
Q2 24
$84.6M
Q1 24
$86.3M
Net Profit
BLLN
BLLN
EB
EB
Q4 25
$-8.2M
Q3 25
$5.7M
$6.4M
Q2 25
$-2.1M
Q1 25
$-6.6M
Q4 24
$-8.4M
Q3 24
$-14.9M
$-3.8M
Q2 24
$1.1M
Q1 24
$-4.5M
Gross Margin
BLLN
BLLN
EB
EB
Q4 25
68.1%
Q3 25
69.9%
67.9%
Q2 25
67.5%
Q1 25
66.9%
Q4 24
68.2%
Q3 24
52.6%
68.5%
Q2 24
70.9%
Q1 24
71.0%
Operating Margin
BLLN
BLLN
EB
EB
Q4 25
-12.4%
Q3 25
11.5%
-1.3%
Q2 25
-8.7%
Q1 25
-13.2%
Q4 24
-10.2%
Q3 24
-32.9%
-11.5%
Q2 24
-7.6%
Q1 24
-8.8%
Net Margin
BLLN
BLLN
EB
EB
Q4 25
-11.1%
Q3 25
6.8%
8.9%
Q2 25
-2.9%
Q1 25
-9.0%
Q4 24
-11.0%
Q3 24
-38.8%
-4.8%
Q2 24
1.3%
Q1 24
-5.2%
EPS (diluted)
BLLN
BLLN
EB
EB
Q4 25
$-0.08
Q3 25
$0.10
$0.06
Q2 25
$-0.02
Q1 25
$-0.07
Q4 24
$-0.09
Q3 24
$-1.47
$-0.04
Q2 24
$0.01
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLLN
BLLN
EB
EB
Cash + ST InvestmentsLiquidity on hand
$195.2M
$299.9M
Total DebtLower is stronger
$55.0M
$144.4M
Stockholders' EquityBook value
$-239.5M
$179.1M
Total Assets
$327.5M
$647.2M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLLN
BLLN
EB
EB
Q4 25
$299.9M
Q3 25
$195.2M
Q2 25
Q1 25
Q4 24
$441.5M
Q3 24
$24.7M
Q2 24
$56.7M
Q1 24
$113.7M
Total Debt
BLLN
BLLN
EB
EB
Q4 25
$144.4M
Q3 25
$55.0M
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
BLLN
BLLN
EB
EB
Q4 25
$179.1M
Q3 25
$-239.5M
$189.1M
Q2 25
$177.2M
Q1 25
$173.3M
Q4 24
$170.2M
Q3 24
$-242.9M
$179.8M
Q2 24
$176.2M
Q1 24
$184.1M
Total Assets
BLLN
BLLN
EB
EB
Q4 25
$647.2M
Q3 25
$327.5M
$744.6M
Q2 25
$784.1M
Q1 25
$812.3M
Q4 24
$752.3M
Q3 24
$817.4M
Q2 24
$894.5M
Q1 24
$952.2M
Debt / Equity
BLLN
BLLN
EB
EB
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLLN
BLLN
EB
EB
Operating Cash FlowLast quarter
$13.8M
$-60.8M
Free Cash FlowOCF − Capex
$6.5M
$-60.9M
FCF MarginFCF / Revenue
7.7%
-82.8%
Capex IntensityCapex / Revenue
8.8%
0.0%
Cash ConversionOCF / Net Profit
2.42×
TTM Free Cash FlowTrailing 4 quarters
$17.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLLN
BLLN
EB
EB
Q4 25
$-60.8M
Q3 25
$13.8M
$36.7M
Q2 25
$-17.5M
Q1 25
$59.4M
Q4 24
$-45.3M
Q3 24
$44.6M
Q2 24
$-32.3M
Q1 24
$68.6M
Free Cash Flow
BLLN
BLLN
EB
EB
Q4 25
$-60.9M
Q3 25
$6.5M
$36.6M
Q2 25
$-17.5M
Q1 25
$59.4M
Q4 24
$-45.3M
Q3 24
$44.4M
Q2 24
$-32.4M
Q1 24
$68.2M
FCF Margin
BLLN
BLLN
EB
EB
Q4 25
-82.8%
Q3 25
7.7%
51.1%
Q2 25
-24.1%
Q1 25
80.4%
Q4 24
-59.2%
Q3 24
57.1%
Q2 24
-38.3%
Q1 24
79.1%
Capex Intensity
BLLN
BLLN
EB
EB
Q4 25
0.0%
Q3 25
8.8%
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.1%
Q1 24
0.4%
Cash Conversion
BLLN
BLLN
EB
EB
Q4 25
Q3 25
2.42×
5.76×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

EB
EB

US$52.0M71%
Other$21.6M29%

Related Comparisons